SINOVAC’s COVID-19 vaccine is approved for use in children over 6 months of age in Hong Kong

Beijing (China), August 03, 2022–( BUSINESS WIRE )–Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a number one provider of biopharmaceuticals in China, introduced that, based mostly on associated medical trials and immunization research for native children and adolescents, the Department of Health of the Hong Kong Government of the People’s Republic of China, Kong Special The administrative area has approved the corporate’s COVID-19 vaccine (titled Coronavac), for children aged six months to a few years.

The vaccination schedule for this age group follows the identical mannequin as for older children. Three doses of the vaccine will probably be used for children aged six months to a few years, with the primary two doses given 28 days aside, the third dose no less than three months after the second dose – and no restrictions on utility. For immunosuppressed children.

The (*6*) Committee on Vaccine-Preventable Diseases and the (*6*) Committee on Emerging and Zoonotic Diseases of the Department of Health’s Centers for Health Protection, together with the Executive Director’s Expert Advisory Panel, issued interim consensus suggestions in opposition to vaccine use. COVID-19 for infants six months of age and older in Hong Kong on August 1, 2022.

In 2021, SINOVAC started Phase III medical trials of its COVID-19 vaccine (Coronavac) in children aged six months to 17 years. Preliminary outcomes present that the vaccine has a great security and immunogenicity profile, with no critical hostile reactions reported six months after two doses of vaccination in children aged six to 35 months.

On February 15, 2022, Coronavac was approved for emergency use in minors and adults over three years of age in Hong Kong. As of August 2022, Coronavac has been approved for use in minors in 14 Latin American nations, together with Chile, Colombia, and Ecuador. , Brazil, in addition to different nations in Asia and Africa.


Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical firm targeted on the analysis and improvement, manufacturing and advertising of vaccines that defend in opposition to human infectious illnesses.

SINOVAC’s product portfolio contains COVID-19, enterovirus 71 (EV71) contaminated hand-foot-and-mouth illness, hepatitis A and B, seasonal influenza, pneumococcal illness, H5N1 pandemic influenza (avian flu), H1N1 influenza (avian flu) . , chickenpox, mumps and polio.

Your COVID-19 vaccine, referred to as CoronaVac®, has been approved for use in greater than 60 nations and territories worldwide. The Hell Live®Hepatitis A vaccine handed WHO prequalification necessities in 2017. EV71 vaccine, inlive®An progressive vaccine that was marketed in China in 2016. In 2022, SINOVAC’s Sabine strain-inactivated polio vaccine (sIPV) was pre-qualified by the WHO.

SINOVAC is the primary firm to obtain approval for its H1N1 flu vaccine, referred to as Panflu.1®, offered in Chinese authorities vaccination campaigns and stockpiling packages. The firm is additionally the only real provider of the H5N1 pandemic influenza vaccine, Panflu®For the Chinese authorities’s storage program.

SINOVAC is constantly engaged in analysis and improvement of new vaccines with extra mixture merchandise in its pipeline and is continuously exploring international market alternatives. The firm plans to interact in higher and deeper commerce and cooperation with different nations and enterprise and industrial organizations.

For extra info, go to the SINOVAC web site:

The unique language textual content of this declaration is the official approved model. Translations are offered as a comfort solely and should seek advice from the textual content in the unique language, which is the one model of the textual content that has authorized impact.

Check out the unique model on


Public relations group

ICR Inc.
Bill Zima
USA: 1-646-308-1707

Leave a Reply

Your email address will not be published.